Olubukola Ayodele
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olubukola Ayodele has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Richard Hansen
Division of Cancer Services, Princess Alexandra Hospital, Metro South Health, Brisbane, Australia
17 shared publications - Abha Anshu Gupta
Division of Haematology/Oncology Princess Margaret Cancer Center, The Hospital for Sick Children Toronto Ontario Canada
17 shared publications - Esmail Mutahar. Al-Ezzi
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
17 shared publications - Abdulazeez Salawu
Department of Medicine, Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
16 shared publications - Alberto Hernando-Calvo
Princess Margaret Cancer Centre, Toronto, ON, Canada
16 shared publications - Albiruni R. Abdul Razak
Toronto Sarcoma Program, Princess Margaret Cancer Center, Toronto, ON, Canada
16 shared publications
Latest Publications
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (10)
Pivotal Role of Environmental Protection Agencies in Global Cancer Control
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (10)
Pivotal Role of Environmental Protection Agencies in Global Cancer Control
- Open Access
- 16 May 2026
- Published by Elsevier in SSRN Electronic Journal
Breast Cancer Inequities Among Black Women: The United Kingdom as an Instructive Example for Global Oncology
Breast cancer remains the most frequently diagnosed malignancy among women worldwide. However, improvements in outcomes have not been equitably distributed. In the United Kingdom, Black women face significantly poorer outcomes compared to their White counterparts, such as diagnoses at later stages, increased prevalence of triple-negative breast cancer, less favourable patient experiences, and lower survival rates. These disparities persist despite universal healthcare, national screening programs, and standardized cancer pathways, indicating that inequities are rooted in systemic shortcomings within health system design and delivery. This analysis uses the UK as a case study to illustrate how inequities manifest throughout the breast cancer pathway, from prevention and screening to treatment, survivorship, and research participation. Factors contributing to these outcomes include lower screening engagement, delayed medical presentation, culturally inappropriate care, insufficient acknowledgment of biological risk factors like dense breast tissue, and under-representation in clinical trials. Furthermore, inconsistent collection of ethnicity-specific cancer data impedes accountability and hinders progress. Such disparities also incur considerable economic costs. Recent modeling conducted in the UK estimates that addressing ethnic inequalities in diagnosis could avert approximately 2,000 deaths annually and result in savings of £180–250 million each year. The following priorities are recommended: targeted community outreach to facilitate early diagnosis, mandatory equity-focused cancer data collection, inclusive research participation, and integration of cultural competence and anti-racist principles within oncology services. Achieving equity should be regarded as a fundamental quality metric in cancer care, serving as a scientific, moral, and economic imperative for global oncology.
- 16 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBreast Cancer Inequities Among Black Women: The United Kingdom as an Instructive Example for Global Oncology
Breast cancer remains the most frequently diagnosed malignancy among women worldwide. However, improvements in outcomes have not been equitably distributed. In the United Kingdom, Black women face significantly poorer outcomes compared to their White counterparts, such as diagnoses at later stages, increased prevalence of triple-negative breast cancer, less favourable patient experiences, and lower survival rates. These disparities persist despite universal healthcare, national screening programs, and standardized cancer pathways, indicating that inequities are rooted in systemic shortcomings within health system design and delivery. This analysis uses the UK as a case study to illustrate how inequities manifest throughout the breast cancer pathway, from prevention and screening to treatment, survivorship, and research participation. Factors contributing to these outcomes include lower screening engagement, delayed medical presentation, culturally inappropriate care, insufficient acknowledgment of biological risk factors like dense breast tissue, and under-representation in clinical trials. Furthermore, inconsistent collection of ethnicity-specific cancer data impedes accountability and hinders progress. Such disparities also incur considerable economic costs. Recent modeling conducted in the UK estimates that addressing ethnic inequalities in diagnosis could avert approximately 2,000 deaths annually and result in savings of £180–250 million each year. The following priorities are recommended: targeted community outreach to facilitate early diagnosis, mandatory equity-focused cancer data collection, inclusive research participation, and integration of cultural competence and anti-racist principles within oncology services. Achieving equity should be regarded as a fundamental quality metric in cancer care, serving as a scientific, moral, and economic imperative for global oncology.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S3: Representativeness of study participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S3: Representativeness of study participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S3: Representativeness of study participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S3: Representativeness of study participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset